BACKGROUND: Medulloblastoma is the most frequent primary solid central nervous system tumour in children. The 5-year survival rate is at present at about 60%. Height in general is severely compromised in survivors. The present study is an extension of the
Final height in children with medulloblastoma treated with growth hormone.All Scholarly Works
Document TypeArticle, Peer-reviewed
Citation InformationHorm Res 2005;64(1):28-34. Epub 2005 Aug 11.